STOCK TITAN
  1. Home
  2. Sec-filings
  3. OVID
  4. [EFFECT] Ovid Therapeutics Inc. SEC Filing

[EFFECT] Ovid Therapeutics Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 22, 2025 4:00 P.M.
Form: S-3
CIK: 0001636651
Company Name: Ovid Therapeutics Inc.
File Number: 333-292151

Source: View Original Filing on SEC EDGAR

Stock OVID logo
Ovid Therapeutics Inc

NASDAQ:OVID

OVID Rankings

#4911 Ranked by Market Cap
N/A Ranked by Dividends

OVID Latest News

Dec 18, 2025
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Dec 2, 2025
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Nov 12, 2025
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Oct 3, 2025
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Oct 3, 2025
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

OVID Latest SEC Filings

Jan 29, 2026
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure
Jan 8, 2026
[SCHEDULE 13G] Ovid Therapeutics Inc. Passive Investment Disclosure (>5%)
Jan 8, 2026
[SCHEDULE 13G] Ovid Therapeutics Inc. Passive Investment Disclosure (>5%)
Dec 18, 2025
[8-K] Ovid Therapeutics Inc. Reports Material Event
Dec 18, 2025
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity

OVID Stock Data

113.23M
117.40M
16.31%
34.69%
1.79%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK